huCART19 / Novartis 
Welcome,         Profile    Billing    Logout  
 0 Diseases   5 Trials   5 Trials   32 News 


12»
  • ||||||||||  huCART19 / Novartis
    Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3726;    
    This trial shows feasibility of manufacturing 4-1BB cells on the Prodigy cost-effectively, with successful manufacture for each pt and all products meeting release criteria. Investigation will continue into the significance of NGS-MRD positivity following Prodigy-manufactured huCART19 therapy, durability of remission, and potentially faster automated GMP manufacturing.
  • ||||||||||  huCART19 / Novartis
    Trial completion, Trial completion date, Trial primary completion date:  Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) -  Sep 20, 2024   
    P2,  N=106, Completed, 
    Investigation will continue into the significance of NGS-MRD positivity following Prodigy-manufactured huCART19 therapy, durability of remission, and potentially faster automated GMP manufacturing. Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
  • ||||||||||  huCART19 / Novartis
    Enrollment open:  CAR-T Cell Therapy for Desensitization in Kidney Transplantation (clinicaltrials.gov) -  May 22, 2024   
    P1,  N=20, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024 Not yet recruiting --> Recruiting
  • ||||||||||  huCART19 / Novartis
    Trial initiation date, CAR T-Cell Therapy:  CAR-T Cell Therapy for Desensitization in Kidney Transplantation (clinicaltrials.gov) -  May 1, 2024   
    P1,  N=20, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Mar 2024 --> May 2024
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania
    Trial completion date, Trial primary completion date:  Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov) -  Dec 19, 2023   
    P1/2,  N=93, Recruiting, 
    Reinfusion of CTL019/tisagenlecleucel or huCART19 is safe, may reduce relapse risk in a subset of patients, and can reinduce remission in CD19-positive relapse. Trial completion date: Jan 2026 --> Jan 2029 | Trial primary completion date: Jan 2025 --> Jan 2027
  • ||||||||||  huCART19 / Novartis
    Enrollment closed, Enrollment change:  Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) -  Aug 9, 2023   
    P2,  N=100, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=63 --> 100
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania
    Enrollment open:  Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov) -  Jan 26, 2023   
    P1/2,  N=93, Recruiting, 
    Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T cell therapy in early lines of multiple myeloma treatment. Not yet recruiting --> Recruiting
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, huCART19 / Novartis
    Academic Development of a Lentiviral Vector vs CD19 (Poster Area) -  Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_122;    
    The extracellular domain that we will use corresponds to the mouse monoclonal antibody that recognizes human CD19 from tisagenlecleucel®. It is feasible to develop a huCART-19 with research grade in Mexico, the next step is to evaluate its function in a clinical model.
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania, SCRI-CAR19x22v2 / Seattle Children's Hospital
    Dual CAR T-Cell for ALL (Level 4, Grand Ballroom G-L) -  Jul 26, 2022 - Abstract #SOHO2022SOHO_52;    
    P1, P1/2
    Quantitative PCR data demonstrated that CART22-65s and huCART19 had different peak expansions that correlated with distinct cytokine release syndrome events...Early results have demonstrated manufacturing feasibility and anti-leukemia activity; however, limited dual functionality has been observed in some products. Longer follow-up and additional studies are needed to ascertain remission durability and to further optimize dual-targeted CARs.
  • ||||||||||  huCART19 / Novartis
    Trial completion date, Trial primary completion date:  Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) -  Jul 26, 2022   
    P2,  N=63, Recruiting, 
    Longer follow-up and additional studies are needed to ascertain remission durability and to further optimize dual-targeted CARs. Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2024
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania
    CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL (GWCC - B401-B402, Level 4) -  Nov 5, 2021 - Abstract #ASH2021ASH_1878;    
    The two different products demonstrated differential expansion and persistence kinetics. Despite prior exposure to CD19- and/or CD22-specific immunotherapies, all evaluable patients achieved CR with uMRD; we continue to monitor CAR T cell persistence and its impact on durability of response.
  • ||||||||||  huCART19 / Novartis
    Trial primary completion date:  Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) -  Sep 16, 2021   
    P2,  N=63, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Sep 2021 Trial primary completion date: Aug 2021 --> Aug 2022
  • ||||||||||  huCART19 / Novartis, MTV273 / Novartis
    Trial primary completion date:  Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma (clinicaltrials.gov) -  Jun 29, 2021   
    P1,  N=40, Active, not recruiting, 
    Trial primary completion date: Aug 2021 --> Aug 2022 Trial primary completion date: May 2022 --> Mar 2036
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania
    Trial completion date, Combination therapy:  CART22 Alone or in Combination With huCART19 for ALL (clinicaltrials.gov) -  Jun 29, 2021   
    P1,  N=23, Active, not recruiting, 
    Trial primary completion date: May 2022 --> Mar 2036 Trial completion date: Sep 2037 --> Jan 2036
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, huCART19 / Novartis
    Yes it is CTL119 (Twitter) -  Jun 24, 2021   
  • ||||||||||  huCART19 / Novartis, MTV273 / Novartis
    Trial primary completion date:  Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma (clinicaltrials.gov) -  May 28, 2021   
    P1,  N=40, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: May 2021 --> May 2022
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, huCART19 / Novartis
    Trial initiation date:  Retreatment With CTL019/CTL119 (clinicaltrials.gov) -  Feb 21, 2021   
    P1,  N=12, Not yet recruiting, 
    Trial primary completion date: May 2021 --> May 2022 Initiation date: Nov 2020 --> Apr 2021
  • ||||||||||  huCART19 / Novartis
    Trial completion date, Trial primary completion date:  Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL (clinicaltrials.gov) -  Feb 3, 2021   
    P2,  N=85, Recruiting, 
    Initiation date: Nov 2020 --> Apr 2021 Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Jan 2021 --> Aug 2021
  • ||||||||||  huCART19 / Novartis, MTV273 / Novartis
    Enrollment closed:  Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma (clinicaltrials.gov) -  Dec 17, 2020   
    P1,  N=40, Active, not recruiting, 
    Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Jan 2021 --> Aug 2021 Recruiting --> Active, not recruiting
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania
    Enrollment closed, Combination therapy:  CART22 Alone or in Combination With huCART19 for ALL (clinicaltrials.gov) -  Dec 17, 2020   
    P1,  N=23, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania
    Trial completion date, Trial primary completion date, Combination therapy:  CART22 Alone or in Combination With huCART19 for ALL (clinicaltrials.gov) -  Nov 5, 2020   
    P1,  N=18, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Sep 2033 --> Sep 2037 | Trial primary completion date: Jan 2021 --> Jan 2036
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, huCART19 / Novartis
    Trial initiation date:  Retreatment With CTL019/CTL119 (clinicaltrials.gov) -  Aug 24, 2020   
    P1,  N=12, Not yet recruiting, 
    Trial completion date: Sep 2033 --> Sep 2037 | Trial primary completion date: Jan 2021 --> Jan 2036 Initiation date: Jul 2020 --> Nov 2020
  • ||||||||||  huCART19 / Novartis, MTV273 / Novartis
    Trial completion date, Trial primary completion date:  Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma (clinicaltrials.gov) -  Jun 25, 2020   
    P1,  N=39, Recruiting, 
    Initiation date: Jul 2020 --> Nov 2020 Trial completion date: May 2021 --> May 2036 | Trial primary completion date: May 2020 --> May 2021
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, huCART19 / Novartis
    New P1 trial:  Retreatment With CTL019/CTL119 (clinicaltrials.gov) -  Jun 8, 2020   
    P1,  N=12, Not yet recruiting, 
  • ||||||||||  huCART19 / Novartis, CART22 / University of Pennsylvania
    Trial primary completion date, Combination therapy:  CART22 Alone or in Combination With huCART19 for ALL (clinicaltrials.gov) -  Feb 11, 2020   
    P1,  N=18, Recruiting, 
    Trial completion date: May 2021 --> May 2036 | Trial primary completion date: May 2020 --> May 2021 Trial primary completion date: Jan 2020 --> Jan 2021